Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Open Access
- 20 June 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (9) , 2631-2640
Abstract
Investigational therapeutics that target toxic species of α-synuclein (αSyn) aim to slow down or halt disease progression in patients with Parkinson’s disease (PD). Here this 44-week, randomized, placebo-controlled, double-blind, single-center phase 1 study investigated safety, tolerability and immunogenicity of UB-312, an active immunotherapeutic targeting pathological αSyn, in patients with PD. The primary outcome measures were adverse event frequency and change in anti-αSyn antibody titers in blood and cerebrospinal fluid (CSF). Exploratory outcomes were changes in clinical scales and biomarker-based target engagement as measured by seed amplification assays. Twenty patients were randomized 7:3 (UB-312:placebo) into 300/100/100 μg or 300/300/300 μg (weeks 1, 5 and 13) intramuscular prime-boost dose groups. Safety was similar across groups; adverse events were mostly mild and transient. Two patients experienced three serious adverse events in total, one possibly treatment related; all resolved without sequalae. Anti-αSyn antibodies in serum from 12/13 and CSF from 5/13 patients who received three UB-312 doses confirmed immunogenicity. Mean serum titers (in log-dilution factor) increased from baseline by 1.398 and 1.354, and peaked at week 29 at 2.520 and 2.133, for 300/100/100 μg and 300/300/300 μg, respectively. CSF titers were 0 at baseline and were 0.182 and 0.032 at week 21, respectively. Exploratory analyses showed no statistical differences in clinical scales but a significant reduction of αSyn seeds in CSF of a subset of UB-312-treated patients. These data support further UB-312 development. ClinicalTrials.gov:NCT04075318.Keywords
Funding Information
- Michael J. Fox Foundation for Parkinson’s Research (MJFF-020184, MJFF-020184, MJFF-020184)
- Michael Fund International Foundation for Genetics Research (MJFF-020184)
This publication has 38 references indexed in Scilit:
- Potential Modes of Intercellular α-Synuclein TransmissionInternational Journal of Molecular Sciences, 2017
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteersMovement Disorders, 2016
- A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcomeJournal of Translational Medicine, 2014
- Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancerJournal of Translational Medicine, 2014
- Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate TransmissionThe Journal of Neuroscience, 2012
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in miceJournal of Experimental Medicine, 2012
- α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregationNature, 2011
- Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-SynucleinJournal of Biological Chemistry, 2002
- Sensitive detection of pathological prion protein by cyclic amplification of protein misfoldingNature, 2001